Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03829436 · ClinicalTrials.gov registry record · Phase 1
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
A Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Tempest Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 11
- Study locations
NCT03829436 is a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer that has completed, run by Tempest Therapeutics. The registered enrollment target is 38 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower). The trial reports 11 study locations across 9 states.
The verdict
NCT03829436, a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, has completed, sponsored by Tempest Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome proliferator activated receptor alpha) as monotherapy and in combination with a systemic anticancer agent, nivolumab, an anti-PD1 antibody, in subjects with advanced solid tumors.
Conditions Studied
Interventions
- DRUG Part 1 TPST-1120
- DRUG Part 2 TPST-1120 + nivolumab
- DRUG Part 3 TPST-1120
- DRUG Part 4 TPST-1120 + nivolumab
Study Locations (11)
Pennsylvania
- University of Pennsylvania Perelman School of Medicine - Philadelphia
- Thomas Jefferson University Hospital - Philadelphia
- UPMC Hillman Cancer Center - Pittsburgh
California
- University of California - San Francisco - San Francisco
Florida
- Miami Cancer Institute - Miami
Maryland
- Johns Hopkins University - Baltimore
Michigan
- University of Michigan Rogel Cancer Center - Ann Arbor
New York
- Columbia University Medical Center - New York
North Carolina
- Carolina BioOncology Institute - Huntersville
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2019-03-20 |
| Est. Completion | 2022-09-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03829436
The ClinicalTrials.gov registry entry for NCT03829436 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Tempest Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Part 1 TPST-1120 is the first listed.
NCT03829436 reports 11 study locations spanning 9 distinct geographic areas - top geographies include Pennsylvania, California, Florida.
Frequently Asked Questions
What is clinical trial NCT03829436 about?
NCT03829436 is a clinical study titled "TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers". This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome proliferator activated receptor alpha) as monotherapy and in combination with...
What is the current status of trial NCT03829436?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2019-03-20. Estimated completion is 2022-09-07.
What conditions does trial NCT03829436 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Triple Negative Breast Cancer.
What interventions are being tested in trial NCT03829436?
The interventions under investigation include: Part 1 TPST-1120 (DRUG), Part 2 TPST-1120 + nivolumab (DRUG), Part 3 TPST-1120 (DRUG), Part 4 TPST-1120 + nivolumab (DRUG).
Who is sponsoring clinical trial NCT03829436?
This trial is sponsored by Tempest Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03829436 being conducted?
This trial has 11 study locations across California, Florida, Maryland, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.